Silence Therapeutics PLC (NAS:SLN)
$ 22.33 1.19 (5.63%) Market Cap: 1.04 Bil Enterprise Value: 973.87 Mil PE Ratio: 0 PB Ratio: 41.35 GF Score: 43/100
Back to the Transcripts List

Silence Therapeutics PLC and Mallinckrodt Plc Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases Transcript

Jul 18, 2019 / 12:00PM GMT
David Horn Solomon
Silence Therapeutics plc - CEO & Director

Thank you very much, and this is David Horn Solomon. I'm the Chief Executive Officer of Silence Therapeutics, and I welcome you all today to our webinar. We're delighted today to announce our collaboration and licensing agreement with Mallinckrodt Pharmaceuticals in complement-mediated diseases, initially focusing on C3.

Before I jump into the details, I want to introduce the team and the agenda, and we'll turn now to the first slide. So joining me on today's call is Giles Campion, our Head of R&D and Chief Medical Officer; Rob Quinn, our CFO; and John Strafford, our Head of Business Development. I'm excited to have these management colleagues with me. Giles has recently joined the company and has vast experience, including at Prosensa, where the company both IPO-ed, had a licensing deal with GSK and was sold to BioMarin; Rob Quinn, who's recently taken on the CFO role after serving in FP&A function in the company and earlier with GSK; and John Strafford, who's recently taken on the role of Head of BD and has been

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.